Log in

NASDAQ:MDCO - The Medicines Stock Price, Forecast & News

$84.90
0.00 (0.00 %)
(As of 02/12/2020)
Today's Range
$84.90
Now: $84.90
$84.90
50-Day Range
$84.90
MA: $84.90
$84.90
52-Week Range
$17.81
Now: $84.90
$84.98
VolumeN/A
Average Volume9.55 million shs
Market Capitalization$6.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.1
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MDCO
CUSIP58468810
Phone973-290-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.14 million
Book Value($0.30) per share

Profitability

Net Income$-123,160,000.00

Miscellaneous

Employees62
Market Cap$6.77 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.


The Medicines (NASDAQ:MDCO) Frequently Asked Questions

What is The Medicines' stock symbol?

The Medicines trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) released its earnings results on Wednesday, October, 30th. The company reported ($0.92) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.12. During the same quarter in the previous year, the company posted ($0.70) earnings per share. View The Medicines' Earnings History.

When is The Medicines' next earnings date?

The Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for The Medicines.

What price target have analysts set for MDCO?

14 equities research analysts have issued 1 year price targets for The Medicines' stock. Their forecasts range from $49.00 to $145.00. On average, they expect The Medicines' stock price to reach $75.08 in the next twelve months. This suggests that the stock has a possible downside of 11.6%. View Analyst Price Targets for The Medicines.

What is the consensus analysts' recommendation for The Medicines?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for The Medicines.

Has The Medicines been receiving favorable news coverage?

Media headlines about MDCO stock have trended neutral this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. The Medicines earned a daily sentiment score of 0.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for The Medicines.

Who are some of The Medicines' key competitors?

What other stocks do shareholders of The Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The Medicines investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), salesforce.com (CRM), AT&T (T), Bank of America (BAC), Ionis Pharmaceuticals (IONS) and Cisco Systems (CSCO).

Who are The Medicines' key executives?

The Medicines' management team includes the folowing people:
  • Mr. Mark Timney, CEO & Director (Age 54)
  • Mr. Christopher J. Visioli, CFO & Treasurer (Age 43)
  • Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 43)
  • Dr. Clive A. Meanwell, Chief Innovation Officer & Director (Age 61)
  • Dr. Goutham Krishna Gorti, VP & Head of Investor Relations

Who are The Medicines' major shareholders?

The Medicines' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Farallon Capital Management LLC (4.16%), Maverick Capital Ltd. (2.73%), Magnetar Financial LLC (2.37%), CNH Partners LLC (1.92%), Iridian Asset Management LLC CT (1.82%) and Westfield Capital Management Co. LP (1.72%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Mark Timney, Melvin K Spigelman, Stephen M Rodin and William Crouse. View Institutional Ownership Trends for The Medicines.

Which institutional investors are selling The Medicines stock?

MDCO stock was sold by a variety of institutional investors in the last quarter, including Graham Capital Management L.P., Mackay Shields LLC, Westfield Capital Management Co. LP, Maverick Capital Ltd., Iridian Asset Management LLC CT, Marshall Wace LLP, Panagora Asset Management Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for The Medicines.

Which institutional investors are buying The Medicines stock?

MDCO stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Magnetar Financial LLC, CNH Partners LLC, IndexIQ Advisors LLC, ARP Americas LP, Beryl Capital Management LLC, Gabelli Funds LLC and Marshall Wace North America L.P.. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox and Mark Timney. View Insider Buying and Selling for The Medicines.

How do I buy shares of The Medicines?

Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is The Medicines' stock price today?

One share of MDCO stock can currently be purchased for approximately $84.90.

How big of a company is The Medicines?

The Medicines has a market capitalization of $6.77 billion and generates $6.14 million in revenue each year. The company earns $-123,160,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. The Medicines employs 62 workers across the globe.View Additional Information About The Medicines.

What is The Medicines' official website?

The official website for The Medicines is http://www.themedicinescompany.com/.

How can I contact The Medicines?

The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]


MarketBeat Community Rating for The Medicines (NASDAQ MDCO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  512 (Thanks for Voting!)
Underperform Votes:  381 (Thanks for Voting!)
Total Votes:  893
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel